Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Avingtrans 570p £203.41m (AVG.L)</li>
<li>The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors announced a trading update regarding the financial year ended 31 May 2026.</li>
<li>The Board reported that profit for the Period will be in line with market expectations and the Group has continued to secure strategically significant contract awards across its core nuclear and infrastructure markets, while also making encouraging progress in expanding its presence in adjacent growth sectors.</li>
</ul>


Avingtrans 570p £203.41m (AVG.L)
The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors announced a trading update regarding the financial year ended 31 May 2026.
The Board reported that profit for the Period will be in line with market expectations and the Group has continued to secure strategically significant contract awards across its core nuclear and infrastructure markets, while also making encouraging progress in expanding its presence in adjacent growth sectors.


<ul>
<li>The clinical stage biotech company has received its first milestone royalty payment of $0.5m from Ligand Pharmaceuticals Incorporated.</li>
<li>This is in relation to AT220, an Arestat-enhanced biosimilar product and under the terms of the Agreement, the first commercial milestone has been achieved, resulting in a $0.5m payment to Arecor.</li>
<li>Arecor expects to receive a further $0.5m in the H2 2026 and the remaining $3m is contingent upon achievement of future commercial milestones which remain on track. </li>
</ul>


The clinical stage biotech company has received its first milestone royalty payment of $0.5m from Ligand Pharmaceuticals Incorporated.
This is in relation to AT220, an Arestat-enhanced biosimilar product and under the terms of the Agreement, the first commercial milestone has been achieved, resulting in a $0.5m payment to Arecor.
Arecor expects to receive a further $0.5m in the H2 2026 and the remaining $3m is contingent upon achievement of future commercial milestones which remain on track. 


<ul>
<li>Abingdon Health 7.75p £18.20m (ABDX.L) The international developer, manufacturer, and distributor of high quality and effective rapid tests announces a new contract win with an expected value of approximately US$2m.</li>
<li>The Company has signed a Master Service Agreement (MSA) with a US-based company for the development and scale up to manufacture of a semi-quantitative, multiplex lateral flow test system.</li>
<li>The MSA covers the feasibility, optimisation, scale-up, and technical transfer to manufacturing of the test for multiple analytes. </li>
</ul>


Abingdon Health 7.75p £18.20m (ABDX.L) The international developer, manufacturer, and distributor of high quality and effective rapid tests announces a new contract win with an expected value of approximately US$2m.
The Company has signed a Master Service Agreement (MSA) with a US-based company for the development and scale up to manufacture of a semi-quantitative, multiplex lateral flow test system.
The MSA covers the feasibility, optimisation, scale-up, and technical transfer to manufacturing of the test for multiple analytes. 


Hybridan Small Cap Feast: 10 November 2025

iFOREX Financial Trading / Equity Bottom-Up

<ul>
<li>Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed.</li>
<li>A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO.</li>
<li>The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. </li>
</ul>


Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed.
A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO.
The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. 


<ul>
<li>12th May: Cobalt Holdings, a Company created primarily to purchase and hold physical cobalt, offering public equity investors pure-play direct exposure to the price of cobalt, confirmed its intention to raise approximately US$230m through its Global Offer and the Admission on to the Main Market on 10 June 2025.</li>
<li>Glencore International AG and certain entities and affiliates managed by Anchorage Structured Commodities Advisor, have agreed to participate as cornerstone investors, agreeing to invest, in aggregate, an amount representing approximately 20.5% of the Shares to be offered pursuant to the Global Offer.</li>
<li>9th May: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announces that it has confirmed its intention to IPO onto the Main Market. </li>
</ul>


12th May: Cobalt Holdings, a Company created primarily to purchase and hold physical cobalt, offering public equity investors pure-play direct exposure to the price of cobalt, confirmed its intention to raise approximately US$230m through its Global Offer and the Admission on to the Main Market on 10 June 2025.
Glencore International AG and certain entities and affiliates managed by Anchorage Structured Commodities Advisor, have agreed to participate as cornerstone investors, agreeing to invest, in aggregate, an amount representing approximately 20.5% of the Shares to be offered pursuant to the Global Offer.
9th May: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announces that it has confirmed its intention to IPO onto the Main Market. 


United Kingdom

Avingtrans designs, manufactures, and supplies engineered components, systems, and associated aftermarket services to the energy, medical, and industrial markets worldwide. The company's products include electric motors, pumps, turbines, gas compressors, pressure vessels, and blast doors. It also provides equipment for medical diagnostic systems, such as 3D X-ray systems and superconducting magnets for MRI. Avingtrans plc was incorporated in 1985 and is based in Chatteris, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avingtrans (AVG LN)

Hybridan Small Cap Feast: 24 June 2026

The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and...

Hybridan

Hybridan Small Cap Feast: 26 March 2026

The clinical stage biotech company has received its first milestone royalty payment of $0.5m from Ligand Pharmaceuticals Incorporated.

Hybridan

Hybridan Small Cap Feast: 10 November 2025

The international developer, manufacturer, and distributor of high quality and effective rapid tests announces a new contract win with an expected...

Hybridan

Hybridan Small Cap Feast: 25/06/2025

A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document

Hybridan

Hybridan Small Cap Feast: 28/05/2025

Cobalt Holdings, a Company created primarily to purchase and hold physical cobalt, offering public equity investors pure-play direct exposure to...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)